274 related articles for article (PubMed ID: 35629333)
41. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
[TBL] [Abstract][Full Text] [Related]
42. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice.
Desjonqueres E; Campani C; Marra F; Zucman-Rossi J; Nault JC
Liver Int; 2022 Mar; 42(3):492-506. PubMed ID: 34982503
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
44. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
45. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
46. Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma.
Jusakul A; Khuntikeo N; Haigh WG; Kuver R; Ioannou GN; Loilome W; Namwat N; Bhudhisawasdi V; Pugkhem A; Pairojkul C; Yongvanit P
Asian Pac J Cancer Prev; 2012; 13 Suppl():77-82. PubMed ID: 23480749
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy Updates in Advanced Hepatocellular Carcinoma.
Singh A; Beechinor RJ; Huynh JC; Li D; Dayyani F; Valerin JB; Hendifar A; Gong J; Cho M
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946408
[TBL] [Abstract][Full Text] [Related]
48. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
49. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
[TBL] [Abstract][Full Text] [Related]
50. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
51. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
52. Cancer Immunology and CAR-T Cells: A Turning Point Therapeutic Approach in Colorectal Carcinoma with Clinical Insight.
Ray SK; Meshram Y; Mukherjee S
Curr Mol Med; 2021; 21(3):221-236. PubMed ID: 32838717
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy in cholangiocarcinoma.
Al-Rajabi R; Sun W
Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
[TBL] [Abstract][Full Text] [Related]
54. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
Hewitt DB; Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
[No Abstract] [Full Text] [Related]
55. Immunotherapy for Breast Cancer: Current and Future Strategies.
Williams AD; Payne KK; Posey AD; Hill C; Conejo-Garcia J; June CH; Tchou J
Curr Surg Rep; 2017 Dec; 5():. PubMed ID: 29657904
[TBL] [Abstract][Full Text] [Related]
56. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
[TBL] [Abstract][Full Text] [Related]
57. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
Mazzolini GD; Malvicini M
Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
[TBL] [Abstract][Full Text] [Related]
58. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment.
Spanu D; Pretta A; Lai E; Persano M; Donisi C; Mariani S; Dubois M; Migliari M; Saba G; Ziranu P; Pusceddu V; Puzzoni M; Astara G; Scartozzi M
World J Hepatol; 2022 Jul; 14(7):1319-1332. PubMed ID: 36158925
[TBL] [Abstract][Full Text] [Related]
59. Liver Inflammation and Hepatobiliary Cancers.
Leone V; Ali A; Weber A; Tschaharganeh DF; Heikenwalder M
Trends Cancer; 2021 Jul; 7(7):606-623. PubMed ID: 33674229
[TBL] [Abstract][Full Text] [Related]
60. Gut microbiome and CAR-T therapy.
Abid MB; Shah NN; Maatman TC; Hari PN
Exp Hematol Oncol; 2019; 8():31. PubMed ID: 31827982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]